

April 15, 2021

skyeBioscience

Skype Bioscience to Present at Upcoming Investment Conferences in April

San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) -- Skype Bioscience, Inc. (OTCQB: SKYE) ("SKYE" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today that Punit Dhillon, CEO, Skype Bioscience will present a virtual corporate overview at the Sequire Cannabis Investor Conference and Planet Microcap Showcase next week. Details are as follows:

Sequire Cannabis Investor Conference

Date: April 20, 2021

Time: 12:30 PM EST; Track 1

Registration Link: <https://bit.ly/3aeOPi2>

Planet Microcap Showcase

Date: April 22, 2021

Time: 10:30 AM EST; Track 1

Registration Link: <https://bit.ly/3mLO9pa>

About Skype Bioscience, Inc.

Skype Bioscience Inc. is a biopharmaceutical company unlocking the pharmaceutical potential of cannabinoids through the development of its proprietary, cannabinoid-derived molecules to treat diseases with significant unmet needs. The company's lead molecule, in preclinical studies, has demonstrated potential as a new class of therapy to lower intraocular pressure in patients with glaucoma or elevated intraocular pressure that is superior to the current standard of care. For more information, please visit: www.skypebioscience.com.

CONTACT

Karam Takhar

VP, Corporate Development & Investor Relations

Email: ir@skypebioscience.com

Phone: (858) 410-0266

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, including statements regarding our product development, business strategy, timing of clinical trials and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "contemplates," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of

these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.



Source: Skye Bioscience, Inc.